itchy glp 1 injection site Tirzepatide-Induced Reaction Tirzepatide Itching at Injection Site:

The FDA initiated an investigation into Victozas potential link to pancreatic cancer in 2013 after safety concerns emerged, and Victoza has been associated with an increased risk of pancreatic cancer in some studies and adverse event reporting, prompting continued evaluation

Given that GLP-1-MK-801 still leads to lean mass loss and food aversion (rather than just satiety), the drug appears to have some undesirable aspects

ParkBBakbakETeohHKrishnarajADennisFQuanAet al

and possibly having direct effects in other organs (heart, brain, immune system)

It thrives on the gastrointestinal mucosa

27 Hence, using Ile 12 in tirzepatide seems not to weaken its GLP-1 activity and to strengthen its GIP activity